Retatrutide (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Retatrutide (research code LY3437943) is a single-molecule triple agonist studied for its combined activity at the GLP-1, GIP and glucagon receptors. Everything below is assembled purely for laboratory and educational reference — it documents how the compound was prepared and dosed across published trials, and is not a recommendation for use in humans or animals.

The 30 mg vial holds three times the material of a 10 mg fill, so it is reconstituted with proportionally more diluent to land on the same convenient concentration. Adding 3.0 mL of bacteriostatic water to a 30 mg vial produces a concentration of 10 mg/mL (10,000 mcg/mL). At that strength every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg, so the titration arithmetic stays identical to the smaller vials while one vial now covers far more of a multi-week schedule.

Standard (Gradual) Titration Schedule

The gradual schedule follows the slow dose-escalation arms used in the Phase 2 program, where the weekly amount was raised roughly every four weeks to keep gastrointestinal tolerability manageable.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water — typically in two passes with a 1 mL syringe — and inject it slowly down the inside wall of the vial, never directly onto the powder pellet.
3. Swirl gently until the powder is fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule climbs to the 12 mg ceiling tested in Phase 2, the cohort that recorded the largest average weight reductions. It escalates faster, and because the 30 mg vial holds plenty of material, even the top 12 mg step is still well within a single fill.

Supplies Needed

• Retatrutide vials (30 mg): ~2 vials for a 12-week gradual run to 6 mg; ~5 vials for a 24-week run to 8 mg; ~2 vials for a 12-week aggressive run.
• Insulin syringes (U-100, 1 mL): 12–24 for a 12-week schedule; 24–48 for 24 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): ~6 mL reconstitutes two 30 mg vials; ~15 mL for a five-vial run.
• Alcohol swabs: a single 100-count box comfortably covers a 12–24 week schedule.

Protocol Overview

• Research goal: model metabolic weight-regulation via simultaneous GLP-1, GIP and glucagon receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2–8 mg standard, up to 12 mg in aggressive arms.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 2 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Target the mid-band (6–8 mg) for the bulk of the published efficacy signal.
• Because one 30 mg vial spans several weeks, track the reconstitution date closely against the in-use shelf life rather than the dose count.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends up to roughly 24 months. Once reconstituted, refrigerate at 2–8 °C and use within about four weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and — because a 30 mg vial is sampled many times — consider aliquoting and freezing portions at −20 °C, thawing each only once.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact across the many draws a 30 mg vial sees.
• Split larger volumes if they exceed a single syringe’s capacity.
• Document each draw — date, volume, remaining material — for reproducibility.

How Retatrutide Works

Retatrutide is a synthetic peptide engineered as a balanced agonist at three incretin and metabolic receptors at once. GLP-1 and GIP agonism enhances glucose-dependent insulin secretion and dampens appetite, while glucagon-receptor activation lifts metabolic rate and promotes energy expenditure. A fatty-acid moiety extends circulation time to a half-life of roughly six days, which is what supports the once-weekly dosing used in trials. This three-way action is what separates it from single (GLP-1) and dual (GLP-1/GIP) agonists in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in trials

• Average body-weight reduction of roughly 22–24% at 48 weeks in the highest-dose obesity cohort (8–12 mg).
• HbA1c reductions of about 1.3–2.0% in the Type 2 diabetes study, with around 82% of participants reaching HbA1c ≤6.5%.
• Every participant on the 8–12 mg doses achieved at least 5% weight loss in the reported cohorts.
• Resolution of hepatic steatosis in more than 80% of high-dose participants, alongside improvements in blood pressure and lipids.

Side effects reported

• Dose-dependent gastrointestinal effects — mild-to-moderate nausea, vomiting and diarrhoea — concentrated during escalation.
• Generally transient and meaningfully reduced by the four-week titration spacing.
• No severe hypoglycaemia or serious treatment-related events were reported in the trials.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the published study designs.
• Combined resistance and aerobic activity to preserve lean mass.
• Adequate sleep, stress management and hydration as standard trial controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Split volume across sites when it exceeds a comfortable single injection.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols